ClinicalTrials.gg
CompletedNCT05337683Updated Jan 28, 2025

A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

An observational study in PNH, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Handok Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

This study is a retrospective non-interventional study, and the main objective of this study is to identify the impact of eculizumab treatment and the improvement of complications before and after eculizumab treatment, and to evaluate the safety during the treatment and the clinical unmet needs during the treatment in PNH patients in real-world.

02

Conditions studied

  • PNH
03

In context

Lead sponsor

Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with PNH aged 18 years or older who started receiving eculizumab treatment accordance with the drug label until January 31, 2020 will be enrolled in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with PNH aged 18 years or older who started eculizumab treatment in accordance with drug label between 2012 and January 31st, 2020. (However, patients who have received eculizumab as part of a clinical trial or an expanded access program/compassionate use program prior to 2012 are also eligible.)
  • Patients who are vaccinated against Neisseria meningitidis at least 2 weeks prior to starting eculizumab treatment. Patients who have been treated with appropriate prophylactic antibiotic therapy for 2 weeks after vaccination if they received eculizumab within 2 weeks after the vaccination.

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients with PNH aged under 18 years
  • Patients with to the active ingredients of eculizumab, murine protein, or other components
  • Patients with untreated severe meningococcal (Neisseria meningitidis) infection
  • Patients who received other complement inhibitors for PNH before or during eculizumab treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
80 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Decrease of hemolysis after eculizumab treatment

    The change in LDH levels before and after eculizumab treatment will be compared to determine whether hemolysis decreased after the treatment.

    Time frame: The results of LDH tests performed before eculizumab treatment, at 6, 12, 24 months after the start of eculizumab treatment, and every 12 months thereafter will be collected.

  2. The Improvement/occurrence of complications and related clinical symptoms before and after eculizumab treatment

    The major complications due to PNH include thromboembolism, pulmonary hypertension, renal failure, and smooth muscle spasm, and their occurrence will be determined by the investigator. In addition, PNH-related symptoms (fatigue, anemia, dysphagia, shortness of breath/dyspnea, chest pain, abdominal pain, erectile dysfunction, hemoglobinuria, others) before and after eculizumab administration will be compared.

    Time frame: 6 months before eculizumab administration to the end of the administration (It is up to subject's treatment period. Through study completion, an average of 51months)

  3. Severity of anemia

    Hb levels will be compared to identify the severity of anemia.

    Time frame: Before the administration, at 6, 12, 24 months after the start of the treatment and every and 12 months thereafter

  4. The required Unit of pRBC transfusion before and after eculizumab treatment

    Time frame: From 1 year before the treatment to the end of the administration (It is up to subject's treatment period. Through study completion, an average of 51months)

  5. Effectiveness Evaluation at Last Follow-Up

    The investigator will perform the final evaluation of the efficacy for entire observation period based on the collected data. The investigator will comprehensively judge and evaluate the decrease of hemolysis occurrence, the improvement and occurrence of complications, and the severity of anemia, etc.

    Time frame: At the last follow-up (At the time of data collection retrospectively)

07

Study locations

1 site
  • Handok
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Aug 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2022
First posted
Apr 20, 2022
StartActual
Dec 11, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Jan 3, 2022
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05337683
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
Dec 11, 2020
Primary completion
Aug 30, 2021
Completion
Jan 3, 2022
Last update
Jan 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion